|
Market Closed -
CBOE
09:00:00 11/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 3.217 EUR | 0.00% |
|
0.00% | -40.37% |
| 09/09 | Evotec Initiates Phase 1 Trial of Potential Smallpox, Mpox Treatment | MT |
| 09/09 | Evotec Commences Early-stage Study of Potential Orthopoxvirus Therapy | MT |
Company Valuation: Evotec SE
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 7,444 | 2,696 | 3,765 | 1,453 | 966.4 | 527.6 | - | - |
| Change | - | -63.78% | 39.63% | -61.41% | -33.49% | -45.41% | - | - |
| Enterprise Value (EV) 1 | 7,099 | 2,485 | 3,787 | 1,669 | 938.7 | 670.4 | 689.7 | 700.8 |
| Change | - | -65% | 52.43% | -55.93% | -43.75% | -28.58% | 2.88% | 1.6% |
| P/E | 32.7x | -15.4x | -45.3x | -7.38x | -9.4x | -2.53x | -6.9x | -157x |
| PBR | 5.44x | 2.27x | 3.37x | 6.89x | 1.19x | 0.82x | 1x | 1.01x |
| PEG | - | 0x | 0.9x | -0x | 0.2x | -0x | 0.1x | 1.6x |
| Capitalization / Revenue | 12x | 3.59x | 4.82x | 1.82x | 1.23x | 0.88x | 0.73x | 0.67x |
| EV / Revenue | 11.5x | 3.31x | 4.85x | 2.09x | 1.19x | 1.12x | 0.95x | 0.89x |
| EV / EBITDA | 66.2x | 24.4x | 57.1x | 74x | 22.8x | -10.4x | 14.6x | 7.41x |
| EV / EBIT | 173x | 119x | -142x | -11.7x | -16.7x | -2.77x | -23.1x | 27x |
| EV / FCF | 2,155x | 114x | -21.4x | -16.8x | -11.5x | -3.93x | -12.1x | 94.3x |
| FCF Yield | 0.05% | 0.88% | -4.67% | -5.95% | -8.71% | -25.4% | -8.26% | 1.06% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.3 | -0.99 | -0.47 | -1.11 | -0.58 | -1.174 | -0.4303 | -0.019 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 618 | 751.4 | 781.4 | 797 | 788.4 | 600.9 | 724.1 | 784.8 |
| EBITDA 1 | 107.3 | 101.7 | 66.35 | 22.56 | 41.1 | -64.22 | 47.3 | 94.62 |
| EBIT 1 | 41 | 20.85 | -26.63 | -142.5 | -56.2 | -242.1 | -29.88 | 25.99 |
| Net income 1 | 215.5 | -175.7 | -83.91 | -196.1 | -103.5 | -202 | -48.25 | 14.39 |
| Net Debt 1 | -345.3 | -211.8 | 22.09 | 216 | -27.66 | 142.8 | 162.2 | 173.2 |
| Reference price 2 | 42.500 | 15.260 | 21.280 | 8.195 | 5.450 | 2.968 | 2.968 | 2.968 |
| Nbr of stocks (in thousands) | 1,75,162 | 1,76,703 | 1,76,936 | 1,77,303 | 1,77,323 | 1,77,749 | - | - |
| Announcement Date | 12/04/22 | 12/05/23 | 24/04/24 | 17/04/25 | 08/04/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 31.04x | 5.6x | 16.76x | 1.05% | 4.55TCr | |
| -20.85x | 240.83x | -22.36x | -.--% | 4.37TCr | |
| 33.71x | 3.27x | 14.1x | -.--% | 4.31TCr | |
| 45.39x | 5.23x | 28.64x | -.--% | 3.94TCr | |
| 27.03x | 8.15x | 20.66x | 0.42% | 3.19TCr | |
| 33.41x | 5.47x | 24.85x | -.--% | 1.64TCr | |
| 23.57x | 2.06x | 8.94x | 1.13% | 1.42TCr | |
| 74.44x | 3.94x | 15.27x | -.--% | 1.33TCr | |
| Average | 30.97x | 34.32x | 13.36x | 0.33% | 3.09TCr | |
| Weighted average by Cap. | 26.17x | 46.68x | 11.79x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EVT Stock
- 0IRF Stock
- Valuation Evotec SE
Select your edition
All financial news and data tailored to specific country editions
